{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:53Z","timestamp":1790612153061,"version":"4.1.0"},"reference-count":135,"publisher":"Korean Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1A5A20224425"],"award-info":[{"award-number":["2018R1A5A20224425"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["e-dmj.org"],"crossmark-restriction":true},"short-container-title":["Diabetes Metab J"],"published-print":{"date-parts":[[2022,7,31]]},"abstract":"<jats:p>Statins are the cornerstone of the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). However, even under optimal statin therapy, a significant residual ASCVD risk remains. Therefore, there has been an unmet clinical need for novel lipid-lowering agents that can target low-density lipoprotein cholesterol (LDL-C) and other atherogenic particles. During the past decade, several drugs have been developed for the treatment of dyslipidemia. Inclisiran, a small interfering RNA that targets proprotein convertase subtilisin\/kexin type 9 (PCSK9), shows comparable effects to that of PCSK9 monoclonal antibodies. Bempedoic acid, an ATP citrate lyase inhibitor, is a valuable treatment option for the patients with statin intolerance. Pemafibrate, the first selective peroxisome proliferator-activated receptor alpha modulator, showed a favorable benefit-risk balance in phase 2 trial, but the large clinical phase 3 trial (PROMINENT) was recently stopped for futility based on a late interim analysis. High dose icosapent ethyl, a modified eicosapentaenoic acid preparation, shows cardiovascular benefits. Evinacumab, an angiopoietin-like 3 (ANGPTL3) monoclonal antibody, reduces plasma LDL-C levels in patients with refractory hypercholesterolemia. Novel antisense oligonucleotides targeting apolipoprotein C3 (apoC3), ANGPTL3, and lipoprotein(a) have significantly attenuated the levels of their target molecules with beneficial effects on associated dyslipidemias. Apolipoprotein A1 (apoA1) is considered as a potential treatment to exploit the athero-protective effects of high-density lipoprotein cholesterol (HDL-C), but solid clinical evidence is necessary. In this review, we discuss the mode of action and clinical outcomes of these novel lipid-lowering agents beyond statins.<\/jats:p>","DOI":"10.4093\/dmj.2022.0198","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T20:27:27Z","timestamp":1658953647000},"page":"517-532","update-policy":"https:\/\/doi.org\/10.4093\/crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins"],"prefix":"10.4093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5601-6691","authenticated-orcid":true,"given":"Kyuho","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0740-8116","authenticated-orcid":true,"given":"Sung Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2567","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz962"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2013.37.6.433"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61350-5"},{"key":"ref4","first-page":"3168","volume-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","author":"Grundy","year":"2019"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0156"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-011-0219-7"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.06.015"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2015.39.2.87"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.2258"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0225"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.118.311227"},{"key":"ref13","first-page":"2531","volume-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","author":"Koren","year":"2014"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.4030"},{"key":"ref15","first-page":"2541","volume-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","author":"Stroes","year":"2014"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.3608"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61399-4"},{"key":"ref18","first-page":"341","volume-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","author":"Raal","year":"2015"},{"key":"ref19","first-page":"1713","volume-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","author":"Sabatine","year":"2017"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.06.049"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.03.004"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv028"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.08.006"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv370"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-016-6685-y"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.12.008"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1801174"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/nejmp1614154"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1913805"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1912387"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2020.09.021"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/343425a0"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13457"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1803917"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16585"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.06.002"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.118.011662"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.08.009"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.06.028"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1806747"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/00043798-199604000-00014"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr112"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.115.306249"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.15829\/1560-4071-2020-3826"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0001"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198711123172001"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.102.1.21"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(05)67667-2"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1001282"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199908053410604"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)60656-3"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-020-0823-5"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.10.006"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.03.032"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1288"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.09.011"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12650"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/bf00229469"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1203859"},{"key":"ref60","first-page":"1540","volume-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","author":"Bowman","year":"2018"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.5205"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1812792"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa652"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22258"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab555"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.122.059410"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.113.301464"},{"key":"ref68","first-page":"474","volume-title":"The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans","author":"Boren","year":"2020"},{"key":"ref69","first-page":"1206","volume-title":"Apolipoprotein C-III levels and incident coronary artery disease risk: the EPIC-Norfolk Prospective Population Study","author":"van Capelleveen","year":"2017"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.102.16.1886"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.118.311476"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1126\/science.1161524"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1308027"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1307095"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.111.300367"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz209"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1715944"},{"key":"ref78","first-page":"264","volume-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","author":"Gouni-Berthold","year":"2021"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01168-z"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab820"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m203215200"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1217552109"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m004029200"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.06.007"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.07.038"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1172\/jci37118"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1002926"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1612790"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.02.030"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2004215"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2031049"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1701329"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa689"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.122.059266"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1510926"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.110.212209"},{"key":"ref97","first-page":"2319","volume-title":"ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk","author":"Talmud","year":"2008"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0705041104"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2010.11.002"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12313"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1210\/en.2016-1894"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2014.01.009"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1009501"},{"key":"ref104","volume-title":"Late Breaker Session 1: A first in-human single ascending dose study of a monoclonal antibody against the ANGPTL3\/8 complex in subjects with mixed hyperlipidaemia","author":"Gaudet"},{"key":"ref105","first-page":"692","volume-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","author":"Tsimikas","year":"2017"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1161\/atv.0000000000000147"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-018-0153-2"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.r060582"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1063"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.038"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0902604"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.801"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.113.002432"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1038\/ncpcardio1456"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)61252-1"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)31009-1"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1905239"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01634-w"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5050"},{"key":"ref120","first-page":"2034","volume-title":"New insights into the determination of HDL structure by apolipoproteins: thematic review series: high density lipoprotein structure, function, and metabolism","author":"Phillips","year":"2013"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.238"},{"key":"ref122","first-page":"572","volume-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","author":"Voight","year":"2012"},{"key":"ref123","first-page":"2073","volume-title":"High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART Study","author":"Ko","year":"2016"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx163"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2017.08.007"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1107579"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00613-5"},{"key":"ref128","first-page":"2021","volume-title":"Apolipoprotein-mediated plasma membrane microsolubilization: role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid","author":"Gillotte","year":"1999"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1097\/00041433-200006000-00005"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0403506101"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5248.518"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1097\/mol.0000000000000349"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.2112"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.2121"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.10.052"}],"updated-by":[{"DOI":"10.4093\/dmj.2022.0295","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000}}],"container-title":["Diabetes &amp; Metabolism Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-dmj.org\/upload\/pdf\/dmj-2022-0198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2022.0198","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-dmj.org\/upload\/pdf\/dmj-2022-0198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:54:24Z","timestamp":1659660864000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2022.0198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,31]]},"references-count":135,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"URL":"https:\/\/doi.org\/10.4093\/dmj.2022.0198","relation":{},"ISSN":["2233-6079","2233-6087"],"issn-type":[{"value":"2233-6079","type":"print"},{"value":"2233-6087","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,31]]},"assertion":[{"value":"2022-06-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-27","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-31","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}